News and Announcements
Prescient Therapeutics Latest Update
- Published April 14, 2015 3:13PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Prescient Therapeutics (formerly Virax Holdings) is a clinical stage oncology company developing novel targeted approaches to treat cancers of high unmet need, such as advanced breast, ovarian, multiple myeloma and acute leukemia.
The company raised A$3M in June 2014 and has in the last 6-months acquired a deep pipeline of products through strategic company acquisitions. Prescients’ pipeline includes a small molecule inhibitor PTX-100 (GGTI 2418), capable of blocking the Ras cancer pathway as well as PTX-200 (TCN-P) which inhibits the AKT pathway, another key pathway that contributes to cancer.
Together these novel drugs provide Prescient the unique ability to run five active clinical trials, within the next 12-months, at some of the worlds best Cancer Centers. The aim is to bring to provide better outcomes for cancer patients around the world.
Their recent announcements include:
- Appendix 3Ys, 30th January
- Appointment and Resignation of Company Secretary and Change to Registered Office, 3rd February
- Prescient Therapeutics Acquires Exclusive Worldwide Licence for Cancer Biomarker p27, 9th February
- Prescient Therapeutics Granted Key U.S. Patents for Novel Cancer Compound PTX-200, 23rd February
- Prescient Therapeutics Half-Year Report, 27th February
- Prescient Therapeutics to Present at 27th Annual Roth Conference, 3rd March
- Prescient Therapeutics Receives Approval from U.S. FDA to Transfer IND Sponsorship for Lead Drug Candidate PTX-200, 1st April
To read the latest ASX documents, please click on the links below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
